QURE

$23.873.92%0.90

시간 외 거래: 23.10-0.77 -3.23%

Uniqure Nv (QURE)

Date: O: H: L: C: Vol:

전일 마감가:

$22.97

열려 있는:

$23.27

하루 거래량:

1,840,820

상대 거래량:

0.96

시가총액:

$1.66B

수익:

$18.09M

순이익/손실:

-$208.87M

주가수익비율:

EPS:

-$3.51

순현금흐름:

-$178.15M

1W 성능:

-1.69%

1M 성능:

+1.75%

6M 성능:

+24.78%

1Y 성능:

-30.39%

1일 변동 폭

$22.87$24.09

1주일 범위

$22.42$26.60

52주 변동 폭

$8.73$51.72

Uniqure Nv 주식 (QURE) 회사 개요

명칭

Uniqure Nv

부문

Healthcare

산업

Biotechnology

전화

1-339-970-7000

주소

PAASHEUVELWEG 25A, AMSTERDAM, Netherlands

직원

221

@uniQure_NV

다음 수익 날짜

2026-11-04

최신 SEC 제출 서류

SEC

X에서 QURE에 대한 토론

시가총액

매출

순이익

현금흐름

주당 순 이익

Uniqure Nv 주식(QURE) 업그레이드 및 다운그레이드

날짜	액션	분석자	등급 변경
2026-10-05	다운그레이드	Barclays	Overweight → Equal Weight
2026-09-02	Resumed	William Blair	Outperform
2026-07-30	업그레이드	Wolfe Research	Peer Perform → Outperform
2026-06-18	업그레이드	Barclays	Equal Weight → Overweight
2026-06-17	업그레이드	Cantor Fitzgerald	Neutral → Overweight
2026-03-11	업그레이드	Mizuho	Neutral → Outperform
2026-03-09	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2026-03-09	업그레이드	Wells Fargo	Equal Weight → Overweight
2026-03-03	다운그레이드	Mizuho	Outperform → Neutral
2026-03-03	다운그레이드	Wells Fargo	Overweight → Equal Weight
2026-03-02	다운그레이드	Cantor Fitzgerald	Overweight → Neutral
2026-03-02	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2026-02-24	개시	Wolfe Research	Peer Perform
2026-01-28	개시	Barclays	Equal Weight
2025-11-04	다운그레이드	William Blair	Outperform → Mkt Perform
2025-08-14	업그레이드	Mizuho	Neutral → Outperform
2025-04-01	Resumed	Chardan Capital Markets	Buy
2024-12-10	업그레이드	Raymond James	Outperform → Strong Buy
2024-10-10	Resumed	Raymond James	Outperform
2024-02-29	다운그레이드	Goldman	Buy → Neutral
2023-12-19	다운그레이드	Mizuho	Buy → Neutral
2022-03-17	업그레이드	UBS	Neutral → Buy
2021-06-15	개시	BTIG Research	Buy
2021-05-21	개시	UBS	Neutral
2021-04-26	Resumed	Credit Suisse	Outperform
2021-04-01	업그레이드	Mizuho	Neutral → Buy
2021-01-07	업그레이드	Guggenheim	Neutral → Buy
2020-11-24	개시	H.C. Wainwright	Buy
2020-11-11	개시	Berenberg	Buy
2020-11-09	개시	Jefferies	Buy
2020-11-04	개시	Cantor Fitzgerald	Overweight
2020-10-23	개시	RBC Capital Mkts	Outperform
2020-08-25	개시	Raymond James	Strong Buy
2020-07-31	업그레이드	Robert W. Baird	Neutral → Outperform
2020-06-25	다운그레이드	Mizuho	Buy → Neutral
2020-06-25	다운그레이드	Robert W. Baird	Outperform → Neutral
2020-06-25	다운그레이드	Wells Fargo	Overweight → Equal Weight
2019-12-03	개시	Cowen	Outperform
2019-12-03	개시	Goldman	Buy
2019-11-05	개시	Credit Suisse	Outperform
2019-10-11	개시	Stifel	Buy
2019-09-25	개시	Bernstein	Outperform
2019-09-12	개시	Mizuho	Buy
2019-07-30	다운그레이드	Guggenheim	Buy → Neutral
2019-07-08	재확인	Cantor Fitzgerald	Overweight
2019-04-12	개시	Piper Jaffray	Overweight
2019-03-29	개시	Robert W. Baird	Outperform

Uniqure Nv (QURE) 재무 분석

기간	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
기간 종료일	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	16.10	27.12	15.84	106.48	524.00
Cost of revenue USD (M)	1.69	1.27	0.07	1.25	24.98
Gross profit USD (M)	-	-	15.78	105.23	499.03
Research and development USD (M)	140.67	143.78	214.86	197.59	143.55
Operating expenses USD (M)	207.82	214.77	298.65	248.39	188.41
Operating income USD (M)	-185.35	-184.29	-282.87	-143.16	310.62
Income before tax USD (M)	-193.34	-237.13	-306.56	-128.26	332.81
Income tax expense USD (M)	5.63	2.43	1.92	-1.47	3.22
Net income USD (M)	-198.97	-239.56	-308.48	-126.79	329.59
Basic EPS USD/shares	-3.46	-4.92	-6.47	-2.71	7.17
Diluted EPS USD/shares	-3.46	-4.92	-6.47	-2.71	7.04
Basic weighted shares shares (M)	57.50	48.65	47.67	46.74	45.99
Diluted weighted shares shares (M)	57.50	48.65	47.67	46.74	46.84
Selling, general and administrative USD (M)	65.46	52.66	74.59	55.06	56.29

Uniqure Nv 주식 (QURE) 내부자 거래

Kapusta Matthew CJul 02 '26
CEO, Managing Director
거래
Option Exercise
비용
$19.39
#주식
21,082
가치 ($)
408,780
#주식 총계
540,309
Kapusta Matthew CJul 02 '26
CEO, Managing Director
거래
Sale
비용
$45.16
#주식
21,082
가치 ($)
952,051
#주식 총계
519,227
Kapusta Matthew CJul 02 '26
Officer
거래
Proposed Sale
비용
$45.15
#주식
21,082
가치 ($)
951,932
#주식 총계
0
Kaye JackJun 30 '26
Director
거래
Sale
비용
$46.44
#주식
21,167
가치 ($)
983,030
#주식 총계
25,996
Abi-Saab WalidJun 30 '26
Chief Medical Officer
거래
Proposed Sale
비용
$46.42
#주식
30,000
가치 ($)
1,392,643
#주식 총계
0
Kaye JackJun 30 '26
Director
거래
Proposed Sale
비용
$46.44
#주식
21,167
가치 ($)
983,033
#주식 총계
0
Abi-Saab WalidJun 30 '26
Chief Medical Officer
거래
Option Exercise
비용
$5.59
#주식
10,000
가치 ($)
55,900
#주식 총계
178,235
Abi-Saab WalidJun 30 '26
Chief Medical Officer
거래
Sale
비용
$46.42
#주식
30,000
가치 ($)
1,392,600
#주식 총계
148,235
Kaye JackJun 30 '26
Director
거래
Option Exercise
비용
$23.44
#주식
21,167
가치 ($)
496,230
#주식 총계
43,056
Abi-Saab WalidJun 26 '26
Chief Medical Officer
거래
Sale
비용
$46.86
#주식
1,434
가치 ($)
67,197
#주식 총계
168,235

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
Kapusta Matthew C	CEO, Managing Director	Jul 02 '26	Option Exercise	$19.39	21,082	408,780	540,309
Kapusta Matthew C	CEO, Managing Director	Jul 02 '26	Sale	$45.16	21,082	952,051	519,227
Kapusta Matthew C	Officer	Jul 02 '26	Proposed Sale	$45.15	21,082	951,932	0
Kaye Jack	Director	Jun 30 '26	Sale	$46.44	21,167	983,030	25,996
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Proposed Sale	$46.42	30,000	1,392,643	0
Kaye Jack	Director	Jun 30 '26	Proposed Sale	$46.44	21,167	983,033	0
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Option Exercise	$5.59	10,000	55,900	178,235
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Sale	$46.42	30,000	1,392,600	148,235
Kaye Jack	Director	Jun 30 '26	Option Exercise	$23.44	21,167	496,230	43,056
Abi-Saab Walid	Chief Medical Officer	Jun 26 '26	Sale	$46.86	1,434	67,197	168,235

Uniqure Nv 주식(QURE)의 최신 뉴스

09:42 AM

All eyes on UniQure earnings amid pivotal Huntington’s therapy review - Investing.com

09:42 AM

04:29 AM

How uniQure's(NASDAQ:QURE) Huntington's Disease Gene Therapy Could Become the World's First Disease-Modifying Treatment - Kalkine

04:29 AM

Nov 02, 2026

uniQure's Gene Therapy BLA for Huntington's Disease Gains FDA Pr - GuruFocus

Nov 02, 2026

FDA Opens Review of uniQure's Huntington's Gene Therapy, With May 2027 Verdict Date - BigGo Finance

Nov 02, 2026

FDA to review uniQure's Huntington's gene therapy, decision due on May 2027 - Reuters

Nov 02, 2026

uniQure Huntington’s Gene Therapy Wins FDA Priority Review, Analyst Bullish - uniQure (NASDAQ:QURE) - Benzinga

Nov 02, 2026

uniQure stock jumps as FDA accepts Huntington’s therapy filing - Investing.com

Nov 02, 2026

uniQure gains FDA priority review for Huntington's gene therapy - Mugglehead Investment Magazine

Nov 02, 2026

uniQure announces FDA acceptance, priority review for ifezuntirgene inilparvovec - TipRanks

Nov 02, 2026

FDA accepts uniQure’s Huntington’s disease gene therapy filing By Investing.com - Investing.com India

Nov 02, 2026

uniQure N.V. (UQ1.F) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 30, 2026

3 Promising Genomics Stocks to Add to Your Portfolio Now - Zacks Investment Research

Oct 30, 2026

uniQure N.V. (UQ1.F) Seasonal returns chart - Yahoo Finance Australia

Oct 30, 2026

Oct 29, 2026

Earnings Preview: UniQure NV to Report Financial Results Pre-market on November 04 - Moomoo

Oct 29, 2026

uniQure N.V. (QURE) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 29, 2026

Oct 28, 2026

uniQure to Announce Third Quarter 2026 Financial Results - GlobeNewswire

Oct 28, 2026

uniQure to Announce Third Quarter 2026 Financial Results - Yahoo Finance

Oct 28, 2026

Oct 23, 2026

uniQure N.V. Estimates – NASDAQ:QURE - TradingView

Oct 23, 2026

Oct 15, 2026

QURE Assumes Buy Rating by UBS -- Price Target Raised to $48 - GuruFocus

Oct 15, 2026

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - marketscreener.com

Oct 15, 2026

uniQure: The Market Graded The Wrong Exam (NASDAQ:QURE) - Seeking Alpha

Oct 15, 2026

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - Yahoo Finance

Oct 15, 2026

Oct 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT - GlobeNewswire Inc.

Oct 13, 2026

Oct 12, 2026

uniQure NV (UQ1.SG) Analyst Insights, Price Targets & Recommendations - Yahoo Finance - Yahoo! Finance Canada

Oct 12, 2026

Oct 08, 2026

uniQure N.V. (QURE) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore

Oct 08, 2026

Oct 07, 2026

Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next - Yahoo Finance

Oct 07, 2026

Oct 06, 2026

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE) - Simply Wall Street

Oct 06, 2026

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop - Business Wire

Oct 06, 2026

uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review

Oct 06, 2026

Oct 05, 2026

UniQure Shares Fall After Barclays Downgrade - marketscreener.com

Oct 05, 2026

Barclays Downgrades UniQure to Equal Weight From Overweight - Moomoo

Oct 05, 2026

Oct 02, 2026

Uniqure N.v Stock Price Forecast. Should You Buy QURE? - StockInvest.us

Oct 02, 2026

Oct 01, 2026

Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy - STAT

Oct 01, 2026

$uniQure NV (QURE.US)$ - Moomoo

Oct 01, 2026

Sep 30, 2026

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire

Sep 30, 2026

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire Inc.

Sep 30, 2026

uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update - Seeking Alpha

Sep 30, 2026

uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research

Sep 30, 2026

uniQure Plunges on Additional Data From Huntington's Disease Study - Yahoo Finance

Sep 30, 2026

uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade) - Seeking Alpha

Sep 30, 2026

EBITDA of uniQure N.V. – HAN:UQ1 - TradingView

Sep 30, 2026

Return on invested capital % of uniQure N.V. – HAN:UQ1 - TradingView

Sep 30, 2026

Sep 29, 2026

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - Morningstar

Sep 29, 2026

Four-year data raise durability questions for uniQure’s Huntington gene therapy - biocentury.com

Sep 29, 2026

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PR Newswire

Sep 29, 2026

QURE와(과) 유사한 종목

Uniqure Nv (QURE)

Uniqure Nv 주식 (QURE) 회사 개요

시가총액

매출

순이익

현금흐름

주당 순 이익

Uniqure Nv 주식(QURE) 업그레이드 및 다운그레이드

Uniqure Nv (QURE) 재무 분석

Uniqure Nv 주식 (QURE) 내부자 거래

Uniqure Nv 주식(QURE)의 최신 뉴스

All eyes on UniQure earnings amid pivotal Huntington’s therapy review - Investing.com

How uniQure's(NASDAQ:QURE) Huntington's Disease Gene Therapy Could Become the World's First Disease-Modifying Treatment - Kalkine

uniQure's Gene Therapy BLA for Huntington's Disease Gains FDA Pr - GuruFocus

FDA Opens Review of uniQure's Huntington's Gene Therapy, With May 2027 Verdict Date - BigGo Finance

FDA to review uniQure's Huntington's gene therapy, decision due on May 2027 - Reuters

uniQure Huntington’s Gene Therapy Wins FDA Priority Review, Analyst Bullish - uniQure (NASDAQ:QURE) - Benzinga

uniQure stock jumps as FDA accepts Huntington’s therapy filing - Investing.com

uniQure gains FDA priority review for Huntington's gene therapy - Mugglehead Investment Magazine

uniQure announces FDA acceptance, priority review for ifezuntirgene inilparvovec - TipRanks

FDA accepts uniQure’s Huntington’s disease gene therapy filing By Investing.com - Investing.com India

Form 8K uniQure N.V. For: 2 November By Investing.com - Investing.com Canada

uniQure Announces FDA Acceptance and Priority Review of the - GlobeNewswire

uniQure N.V. (QURE) Stock Price, News, Quote & History - Yahoo! Finance Canada

uniQure N.V. (QURE) Seasonal returns chart - Yahoo Finance UK

uniQure N.V. (UQ1.F) Seasonal returns chart - Yahoo Finance UK

uniQure N.V. (UQ1.F) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

3 Promising Genomics Stocks to Add to Your Portfolio Now - Zacks Investment Research

uniQure N.V. (UQ1.F) Seasonal returns chart - Yahoo Finance Australia

Earnings Preview: UniQure NV to Report Financial Results Pre-market on November 04 - Moomoo

uniQure N.V. (QURE) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

uniQure to Announce Third Quarter 2026 Financial Results - GlobeNewswire

uniQure to Announce Third Quarter 2026 Financial Results - Yahoo Finance

uniQure N.V. Estimates – NASDAQ:QURE - TradingView

QURE Assumes Buy Rating by UBS -- Price Target Raised to $48 - GuruFocus

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - marketscreener.com

uniQure: The Market Graded The Wrong Exam (NASDAQ:QURE) - Seeking Alpha

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - Yahoo Finance

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT - GlobeNewswire Inc.

uniQure NV (UQ1.SG) Analyst Insights, Price Targets & Recommendations - Yahoo Finance - Yahoo! Finance Canada

uniQure N.V. (QURE) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore

Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next - Yahoo Finance

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE) - Simply Wall Street

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop - Business Wire

uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review

UniQure Shares Fall After Barclays Downgrade - marketscreener.com

Barclays Downgrades UniQure to Equal Weight From Overweight - Moomoo

Uniqure N.v Stock Price Forecast. Should You Buy QURE? - StockInvest.us

Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy - STAT

$uniQure NV (QURE.US)$ - Moomoo

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire Inc.

uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update - Seeking Alpha

uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research

uniQure Plunges on Additional Data From Huntington's Disease Study - Yahoo Finance

uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade) - Seeking Alpha

EBITDA of uniQure N.V. – HAN:UQ1 - TradingView

Return on invested capital % of uniQure N.V. – HAN:UQ1 - TradingView

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - Morningstar

Four-year data raise durability questions for uniQure’s Huntington gene therapy - biocentury.com

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PR Newswire

QURE와(과) 유사한 종목